Emerging drugs for neuropathic pain

Expert Opinion on Emerging Drugs

Volumn 19, Issue 3, 2014, Pages 329-341

  Gilron, Ian ^a   Dickenson, Anthony H ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chronic pain; Clinical trials; Experimental models; Neuralgia; Neuropathic pain; Neuropathy; Pharmaceutical development; Preclinical research; Radiculopathy

Indexed keywords

ANALGESIC AGENT;

ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG DESIGN; DRUG SCREENING; HUMAN; NEURALGIA; PATHOPHYSIOLOGY;

ANALGESICS; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; NEURALGIA;

EID: 84906817622     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2014.915025     Document Type: Review

References (84)

1. Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain 2011;152(10):2204-5
2. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9(8):807-19
3. Gilron I, Watson CP, Cahill CM, et al. Neuropathic pain: a practical guide for the clinician. CMAJ 2006;175(3):265-75
4. Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep 2012;16(3):191-8
5. Bouhassira D, Lantéri-Minet M, Attal N, et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380-7
6. Torrance N, Smith BH, Bennett MI, et al. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006;7(4):281-9
7. Atlas SJ, Deyo RA, Patrick DL, et al. The Quebec Task Force classification for Spinal Disorders and the severity, treatment, and outcomes of sciatica and lumbar spinal stenosis. Spine 1996;21:2885-92
8. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004;5:344-56
9. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350-4
10. Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain 2012;13(8):715-24
11. O'Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 2009;27(2):95-112
12. Turk DC. Clinical effectiveness and costeffectiveness of treatments for patients with chronic pain. Clin J Pain 2002;18(6):355-65
13. Backonja MM, Galer BS. Pain assessment and evaluation of patients who have neuropathic pain. Neurol Clin 1998;16(4):775-90
14. Chen H, Lamer TJ, Rho RH, et al. Contemporary management of neuropathic pain for the primary care physician. Mayo Clin Proc 2004;79(12):1533-45
15. Smith BH, Lee J, Price C, et al. Neuropathic pain: a pathway for care developed by the British Pain Society. Br J Anaesth 2013;111(1):73-9
16. Heutink M, Post MW, Bongers-Janssen HM, et al. The CONECSI trial: results of a randomized controlled trial of a multidisciplinary cognitive behavioral program for coping with chronic neuropathic pain after spinal cord injury. Pain 2012;153(1):120-8
17. Attal N, Cruccu G, Baron R, et al. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17(9):1113-e88
18. Dworkin RH, O'Connor AB, Kent J, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain 2013;154(11):2249-61
19. Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94(2):149-58
20. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150(3):573-81
21. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev 2009;7(4):CD007115
22. Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009;8(3):CD007076
23. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(3 Suppl):S3-14
24. Moulin DE, Clark AJ, Gilron I, et al. Canadian Pain Society. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;Spring 12(1):13-21
25. Berger A, Toelle T, Sadosky A, et al. Clinical and economic characteristics of patients with painful neuropathic disorders in Germany. Pain Pract 2009;9(1):8-17
26. Berger A, Sadosky A, Dukes E, et al. Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study. BMC Neurol 2012;12:8
27. Gore M, Dukes E, Rowbotham DJ, et al. Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eur J Pain 2007;11(6):652-64
28. Lachaine J, Gordon A, Choinière M, et al. Painful neuropathic disorders: an analysis of the Régie de l'Assurance Maladie du Québec database. Pain Res Manag 2007;Spring 12(1):31-7
29. Torrance N, Smith BH, Watson MC, et al. Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin. Fam Pract 2007;24(5):481-5
30. Vo T, Rice AS, Dworkin RH. Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use? Pain 2009;143(3):169-71
31. Dickenson AH, Matthews EA, Suzuki R. Neurobiology of neuropathic pain: mode of action of anticonvulsants. Eur J Pain 2002;6(Suppl A):51-60
32. Baron R, Hans G, Dickenson AH. Peripheral input and its importance for central sensitization. Ann Neurol 2013;74(5):630-6
33. Bannister K, Bee LA, Dickenson AH. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics 2009;6(4):703-12
34. Beggs S, Salter MW. Microglia-neuronal signalling in neuropathic pain hypersensitivity 2.0. Curr Opin Neurobiol 2010;20(4):474-80
35. Ellis A, Wieseler J, Favret J, et al. Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain. J Pain 2014. [Epub ahead of print]
36. Sikandar S, Dickenson AH. No need for translation when the same language is spoken. Br J Anaesth 2013;111(1):3-6
37. Sikandar S, Patel R, Patel S, et al. Genes, molecules and patients-emerging topics to guide clinical pain research. Eur J Pharmacol 2013;716(1-3):188-202
38. King T, Vera-Portocarrero L, Gutierrez T, et al. Unmasking the tonicaversive state in neuropathic pain. Nat Neurosci 2009;12(11):1364-6
39. Sikandar S, Ronga I, Iannetti GD, et al. Neural coding of nociceptive stimulifrom rat spinal neurones to human perception. Pain 2013;154(8):1263-73
40. Gilron I, Coderre TJ. Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs 2007;12:113-26
41. Goodman M. Pharmaceutical industry financial performance. Nat Rev Drug Discov 2009;8(12):927-8
42. O'Neill J, Brock C, Olesen AE, et al. Unravelling the mystery of capsaicin: a tool to understand and treat pain. Pharmacol Rev 2012;64(4):939-71
43. Peppin JF, Pappagallo M. Capsaicinoids in the treatment of neuropathic pain: a review. Ther Adv Neurol Disord 2014;7(1):22-32
44. Hardaway AL, Podgorski I. IL-1beta, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies. Future Med Chem 2013;5(10):1089-108
45. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010;363(16):1521-31
46. Seidel MF, Wise BL, Lane NE. Nerve growth factor: an update on the science and therapy. Osteoarthritis Cartilage 2013;21(9):1223-8
47. Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 2006;29:507-38
48. Seidel MF, Wise BL, Lane NE. Nerve growth factor: an update on the science and therapy. Osteoarthritis Cartilage 2013;21(9):1223-8
49. Leite VF, Buehler AM, El Abd O, et al. Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis. Pain Physician 2014;17(1):E45-60
50. Waxman SG, Zamponi GW. Regulating excitability of peripheral afferents: emerging ion channel targets. Nat Neurosci 2014;17(2):153-63
51. Smith MT, Woodruff TM, Wyse BD, et al. A small molecule Angiotensin II type 2 receptor (AT(2) R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root Ganglia. Pain Med 2013;14(10):1557-68
52. Rice AS, Dworkin RH, McCarthy TD, et al. for the EMA401-003 study group. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2014. [Epub ahead of print]
53. Anand U, Facer P, Yiangou Y, et al. Angiotensin II type 2 receptor (AT2 R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur J Pain 2013;17(7):1012-26
54. Colpaert FC. 5-HT(1A) receptor activation: new molecular and neuroadaptive mechanisms of pain relief. Curr Opin Investig Drugs 2006;7(1):40-7
55. Medhurst SJ, Collins SD, Billinton A, et al. Novel histamine H3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgicallyinduced and virally-induced rat models of neuropathic pain. Pain 2008;138(1):61-9
56. Passani MB, Lin JS, Hancock A, et al. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004;25(12):618-25
57. Yarnitsky D, Granot M, Nahman-Averbuch H, et al. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain 2012;153(6):1193-8
58. Heinricher MM. Nociceptin/orphanin FQ: pain, stress and neural circuits. Life Sci 2005;77(25):3127-32
59. Li JX, Zhang Y. Emerging drug targets for pain treatment. Eur J Pharmacol 2012;681(1-3):1-5
60. Maurice T, Su TP. The pharmacology of sigma-1 receptors. Pharmacol Ther 2009;124(2):195-206
61. Martín-Sánchez E, Furukawa TA, Taylor J, et al. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med 2009;10(8):1353-68
62. Robson PJ. Therapeutic potential of cannabinoid medicines. Drug Test Anal 2014;6(1-2):24-30
63. Chiou LC, Lee HJ, Ho YC, et al. Orexins/hypocretins: pain regulation and cellular actions. Curr Pharm Des 2010;16(28):3089-100
64. Hoyer D, Jacobson LH. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand? Neuropeptides 2013;47(6):477-88
65. Kang R, Zhang Q, Zeh HJ III, et al. HMGB1 in cancer: good, bad, or both? Clin Cancer Res 2013;19(15):4046-57
66. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-15
67. Dworkin RH, Turk DC, Katz NP, et al. Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION. Pain 2011;152(Suppl 3):S107-15
68. Quessy SN. Where are the new analgesics? An alternative approach to early phase analgesic trials using a multivariable input model with adaptively allocated enrichment. Pain 2010;151(2):247-50
69. Gilron I. Drug discovery for neuropathic pain. In: Simpson DM, McArthur JC, Dworkin RH, editors. Neuropathic Pain: Mechanisms, Diagnosis, and Treatment. Oxford University Press; New York: 2012. p. 38-57
70. Woolf CJ. Overcoming obstacles to developing new analgesics. Nat Med 2010;16(11):1241-7
71. Andrews N, Legg E, Lisak D, et al. Spontaneous burrowing behaviour in the rat is reduced by peripheral nerve injury or inflammation associated pain. Eur J Pain 2012;16(4):485-95
72. Kawasaki-Yatsugi S, Nagakura Y, Ogino S, et al. Automated measurement of spontaneous pain-associated limb movement and drug efficacy evaluation in a rat model of neuropathic pain. Eur J Pain 2012;16(10):1426-36
73. Rice AS, Cimino-Brown D, Eisenach JC, et al. Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards. Pain 2008;139(2):243-7
74. Chen C, Beckman RA. Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions. J Biopharm Stat 2009;19(3):424-36
75. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 2012;153(6):1148-58
76. Maier C, Baron R, Tölle TR, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 2010;150(3):439-50
77. Woolf CJ, Max MB. Mechanism-based pain diagnosis: issues for analgesic drug development. Anesthesiology 2001;95(1):241-9
78. von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 2012;73(4):638-52
79. Freeman R, Baron R, Bouhassira D, et al. Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs. Pain 2014;155(2):367-76
80. Baron R, Förster M, Binder A. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol 2012;11(11):999-1005
81. Basbaum AI, Bautista DM, Scherrer G, et al. Cellular and molecular mechanisms of pain. Cell 2009;139:267-84
82. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352(13):1324-34
83. Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009;374(9697):1252-61
84. Gilron I, Jensen TS, Dickenson AH. Combination pharmacotherapy for management of chronic pain: from bench to bedside. Lancet Neurol 2013;12(11):1084-95